Loading
An adhesion protein on almost all carcinoma cells and the capture molecule for circulating tumour cell tests; the target of the first bispecific antibody ever approved (catumaxomab, 2009). This dossier gathers the 2 products (1 approved), 4 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
Type I transmembrane glycoprotein mediating Ca-independent homotypic cell adhesion; regulated intramembrane proteolysis releases EpICD, which co-activates Wnt/β-catenin target genes (c-MYC, cyclin D1).
| Cancer | Prevalence | Measure | Note | Source |
|---|---|---|---|---|
| Colorectal cancer | 97.7% | IHC, high-level EpCAM expression (TMA, n=1186) | Only 0.4% EpCAM-negative; 92.1% in grade 3 tumours | doi.org |
| Gastric & gastro-oesophageal junction cancer | 90.7% | IHC, high-level EpCAM expression (TMA, n=473) | 2.5% EpCAM-negative | doi.org |
| Pancreatic ductal adenocarcinoma | 78% | IHC, strong EpCAM expression in pancreatic adenocarcinoma (multi-tumour TMA, 3900 samples) | doi.org |
Approximate, population-level figures; the measure column says what was counted. Ranges show the midpoint as a bar.
| Modality | Approved | Phase 3 |
|---|---|---|
| Bispecific antibody 2 |
| Trial | Setting | Result | Products | ||
|---|---|---|---|---|---|
| 3 | Active | A Randomized, Controlled, Multi-Center Phase III Clinical Study to Evaluate the Efficacy and Safety of M701 for Intraperitoneal Injection in Patients With Malignant Ascites Caused by Advanced Epithelial Solid Tumors | - | ||
| 2 | Completed | An Open-Label, Single-Arm, Phase II Safety and Tolerability Study of Catumaxomab (Anti-EpCAM x Anti-CD3) in Women With Advanced Epithelial Ovarian Cancer After a Complete Response to Chemotherapy | - | ||
| 2 | Completed | Multicenter, Single-arm, Phase II Study of the Trifunctional Antibody Catumaxomab (Anti-EpCAM x Anti-CD3) Administered Intra- and Postoperatively in Patients With Epithelial Ovarian Cancer | - | ||
| 2 | Completed | Randomized, Multicenter, 2-Dose Level. Open-Label, Phase IIa Study With the Intraperitoneally Infused Trifunctional Bispecific Antibody Removab(TM) (Anti-EpCAM x Anti-CD3) to Select the Better Dose Level in Platinum Refractory Epithelial Ovarian Cancer Patients | - |
No recorded escape route names this target.
No pathway diagram carries this target as a node.
No companion diagnostic in the registry measures this target.
No model entry for this target yet; check the cancer entries on the models page.
No open questions recorded for this target yet. Suggest one.
Query for this target: (TITLE:"EpCAM" OR ABSTRACT:"EpCAM" OR TITLE:"EPCAM" OR ABSTRACT:"EPCAM") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about EpCAM, not a curated reading list.
The dossier as machine-readable JSON, at /api/v1/dossiers/epcam.json: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/epcam.json. Licence CC BY-NC 4.0.